March 16, 2026
We are pleased to announce the release of our ESG report for 2024/2025, which describes our collective progress across environmental sustainability, social responsibility and ethical governance.
It was a cold Thursday evening but that did not stop the MedComms business community coming out to celebrate 10 years of MedComms Networking at an event organized by Peter Llewellyn – and the Oxford PharmaGenesis team were well represented!
London, UK, 17 January 2017 – The American Medical Writers Association (AMWA), European Medical Writers Association (EMWA), and International Society for Medical Publication Professionals (ISMPP) today released a Joint Position Statement on the Role of Professional Medical Writers, which is the first unified position on the role of professional medical writers from three leading professional…
The expertise of Oxford PharmaGenesis in planning and communicating real-world evidence (RWE) was showcased in a leader published online this month by eyeforpharma.
Every year at Oxford PharmaGenesis, we select a charity so that we can make a donation in lieu of sending cards. This year, we are very pleased to support Evidence Aid, an organization that aims to inspire and enable those guiding the humanitarian sector to apply an evidence-based approach.
Oxford PharmaGenesis has recently become a mentor to a newly established patient group that aims to improve the lives of people affected by certain rare genetic disorders.
The theme of this year’s World Orphan Drug Congress (WODC) Europe was ‘strategy, advocacy and partnering for the world of orphan drugs and rare diseases’, which offered a great opportunity for Oxford PharmaGenesis to showcase our experience in the area of patient engagement.
